Praxis Precision Medicines (PRAX) Liabilities and Shareholders Equity (2019 - 2026)

Praxis Precision Medicines' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 205.01% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $3.2 billion (up 78.51% YoY), while the FY2025 annual figure was $937.9 million, up 94.14% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.5 billion, up from $937.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.5 billion in Q1 2026, with the low at $87.9 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $250.4 million (2024), against an average of $377.4 million.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity sank 60.67% in 2022, then jumped 449.31% in 2024.
• Praxis Precision Medicines' Liabilities and Shareholders Equity stood at $115.1 million in 2022, then dropped by 23.61% to $87.9 million in 2023, then surged by 449.31% to $483.1 million in 2024, then soared by 94.14% to $937.9 million in 2025, then soared by 55.69% to $1.5 billion in 2026.
• Business Quant data shows PRAX's Liabilities and Shareholders Equity at $1.5 billion in Q1 2026, $937.9 million in Q4 2025, and $396.4 million in Q3 2025.